COMMUNIQUÉS West-GlobeNewswire

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site
20/05/2025
USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologies CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s [...]
Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic
20/05/2025
The program, licensed exclusively to BMS, represents the third ADC candidate using the company’s proprietary Tubutecan technology to reach the clinic. MUNICH, GERMANY, May 20, 2025 – Tubulis today announced that the [...]
Actimed Therapeutics Announces New Programme to Investigate Potential Muscle Preservation Effects of S-pindolol Benzoate in Obese Patients Treated with GLP-1 Agonists
20/05/2025
Two-part preclincal and clinical development programme launched to assess potential benefits of administering S-pindolol benzoate during and post-GLP-1 receptor agonist therapy to improve muscle mass, cardiac protection [...]
EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer
20/05/2025
These results indicate that EXACT Therapeutics’ Acoustic Cluster Therapy (ACT ® ) significantly enhances the local effect of chemotherapy In the patients who had a response to chemotherapy, ACT-treated tumours showed a [...]
AB Science announces the successful completion of a EUR 1.8 million private placement
20/05/2025
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 1.8 MILLION PRIVATE PLACEMENT Paris, May 20, 2025, 8am AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) announces [...]
AB Science annonce le succès d'un placement privé de 1,8 millions d'euros
20/05/2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE SUCCES D’UN PLACEMENT PRIVE D’ENVIRON 1,8 MILLION D’EUROS Paris, 20 mai 2025, 8h AB Science S.A. (la “ Société ” ou “ AB Science ”, Euronext – FR0010557264 – AB) annonce [...]
CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
20/05/2025
Press Release CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval The [...]
CROSSJECT prépare le lancement d’une augmentation de capital avec maintien du droit préférentiel de souscription d’un montant d’environ 5 millions d’euros en préparation des activités commerciales et de production liées à l’approbation EUA
20/05/2025
Communiqué de presse CROSSJECT prépare le lancement d’une augmentation de capital avec maintien du droit préférentiel de souscription d’un montant d’environ 5 millions d’euros en préparation des activités commerciales [...]
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States
20/05/2025
Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections [...]
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer
20/05/2025
Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC Antibody Formats Towards Clinical Studies VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and [...]
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
20/05/2025
BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of [...]
Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results
19/05/2025
Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent Reports continued progress on the development of the user-filled Optejet, and [...]
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
19/05/2025
CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications [...]
KabaFusion Acquires Infusion Care Assets from Coram® to Expand its Nationwide Footprint of Patient-Focused Services
19/05/2025
Expansion to Increase KabaFusion’s Footprint to 32 Specialty Pharmacies and 19 Ambulatory Infusion Suites Across 26 States LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- KabaFusion, a nationally recognized leader in [...]
Aurora Spine Corporation Schedules Release of First Quarter Fiscal 2025 Financial Results
19/05/2025
CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal [...]
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/05/2025
WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that [...]
CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies
19/05/2025
-Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small interfering RNA (siRNA) for the treatment of thromboembolic [...]
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
19/05/2025
Company’s first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammation Novel bispecific design [...]
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions
19/05/2025
Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian Zapf, J.D., appointed [...]

Pages